Login / Signup

The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines.

Mine Durusu TanrioverÖzlem Altuntaş AydınHatice Rahmet GünerOrhan Yıldızİlhami CelikSukran KoseSila AkhanEmin Halis AkalınAykut ÖzdarendeliSerhat Unalİhsan AteşAteş Karanull null
Published in: Human vaccines & immunotherapeutics (2024)
This study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in Türkiye- evaluated the impact of previous SARS-CoV-2 infection before the first dose of inactive TURKOVAC on post-vaccine local and systemic adverse events (AEs) comparing with CoronaVac. Of 1266 participants analyzed, 27.7% had a previous COVID-19 history. Local and systemic AEs were observed in 37.3% and 39% of the participants. The frequency of AEs was slightly higher in the first 30 minutes and 24 hours among participants with a COVID-19 history; none were severe. 1203 participants had a second dose vaccination, and 27.3% had a history of COVID-19. The frequencies of local and systemic AEs after the second dose were similar between those with and without a COVID-19 history. The TURKOVAC and CoronaVac showed similar frequencies of local and systemic AEs in the first 30 minutes after vaccination.
Keyphrases
  • coronavirus disease
  • sars cov
  • respiratory syndrome coronavirus
  • clinical trial
  • drug induced
  • early onset
  • machine learning
  • study protocol